Healogics recently appointed John P. Landino as its new Chief Development Officer. Specifically, Landino will spearhead growth strategies for the nation’s leading advanced wound care provider. He brings nearly 20 years of specialized experience in business development. Previously, he held senior leadership roles at Fresenius Medical Care and Tenet Healthcare. His background includes building vital partnerships with hospital executives and healthcare leaders.
Furthermore, John P. Landino will focus on creating new business opportunities to expand the company’s mission. This appointment arrives as Healogics celebrates 30 Years of Healing. Consequently, the organization aims to further strengthen its commitment to clinical innovation. Meanwhile, his leadership will support rapid and sustainable growth across the network. Additionally, he will oversee initiatives to enhance physician engagement nationwide.
“John’s extensive experience in healthcare development and his innovative approach make him an ideal leader for our growth initiatives,” said Pamela Mandel, Chairman and Chief Executive Officer of Healogics. “We are thrilled to welcome him to our executive team, and we look forward to working together as we continue to strengthen our partnerships and expand access to advanced wound care in more communities.”
Notably, Healogics remains the top provider of hyperbaric oxygen therapy services. Therefore, Landino’s role is crucial for shaping the future of the healing process. Moreover, his expertise in forging strategic alliances will benefit various healthcare sectors.
“I could not be more excited to be part of Healogics, the nation’s leading wound care organization,” said John. “The company’s track record of innovation and impact makes this an incredible opportunity. I look forward to working with our team and partners to expand our reach and help shape the future of healing for communities nationwide.”
For more stories on technology leaders shaping the future of enterprise solutions, visit our CXO Insiders.
Source: PRNewswire
